H
Helen B Higgins
Researcher at University of Warwick
Publications - 28
Citations - 437
Helen B Higgins is an academic researcher from University of Warwick. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 7, co-authored 24 publications receiving 330 citations.
Papers
More filters
Journal ArticleDOI
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl,Helena M. Earl,Helena M. Earl,Louise Hiller,Anne-Laure Vallier,Shrushma Loi,Karen McAdam,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Sanjay Raj,Pamela Woodings,Mark Harries,Donna L. Howe,Kerry Raynes,Helen B Higgins,Maggie Wilcox,Chris Plummer,Chris Plummer,Janine Mansi,Ioannis Gounaris,Betania Mahler Araujo,Elena Provenzano,Elena Provenzano,Anita Chhabra,Jean Abraham,Jean Abraham,Jean Abraham,Carlos Caldas,Peter Hall,Christopher McCabe,Claire Hulme,Claire Hulme,David Miles,Andrew M Wardley,David Cameron,Janet A. Dunn,Roshan Agarwal,Hafiz Algurafi,Rozenn Allerton,Caroline Archer,Anne C Armstrong,Catherine Bale,Lisa H Barraclough,Urmila Barthakur,Carolyn Bedi,Kim Benstead,D. Bloomfield,Rebecca Bowen,Chris Bradley,Jane Brown,Mohammad Butt,Mark Churn,Susan Cleator,Joanne Cliff,Perric Crellin,Margaret Daly,Shiroma De Silva-Minor,A.S. Dhadda,O.S. Din,Sue Down,H. M. Earl,David J. Eaton,Andrew Eichholz,Daniel Epurescu,Chee Goh,Andrew D. Goodman,Robert Grieve,Maher Hadaki,Catherine Harper-Wynne,Larry Hayward,A. Humphreys,Helen Innes,Mariam Jafri,Apurna Jegannathen,Muireann Kelleher,Hartmut Kristeleit,Daniela Lee,Susan Lupton,Carol MacGregor,Zafar Malik,Jennifer Marshall,Trevor McGolick,Rakesh Mehra,Natasha Mithal,Charlotte Moss,Aian Moss,Mukesh Mukesh,Anthony Neal,Daniel Nelmes,Helen Neville-Webbe,Jacqueline Newby,S O'Reilly,Peter Ostler,Mojca Persic,Laura Pettit,Fharat A. Raja,Catherine Reed,Anne Rigg,Helen Roe,Nihal Shah,Peter Simmonds,Eliot Sims,Sarah Smith,Nicola Storey,Wendy Taylor,Narottam Thanvi,Karen Tipples,Jayant S. Vaidya,Mohini Varughese,Anup Vinayan,Nawaz Walji,Simon Waters,Kathryn Wright,Sundus Yahya +117 more
TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.
Journal ArticleDOI
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
Mark T. Drayson,Stella Bowcock,Tim Planche,Gulnaz Iqbal,Guy Pratt,Kwee Yong,Jill Wood,Kerry Raynes,Helen B Higgins,Bryony Dawkins,David Meads,Claire Hulme,Irene M. Monahan,Kamaraj Karunanithi,Helen Dignum,Edward Belsham,Jeff Neilson,Beth Harrison,Anand Lokare,Gavin Campbell,Michael R. Hamblin,Peter M. Hawkey,Anna C. Whittaker,Eric Low,Janet A. Dunn,Trial Investigators +25 more
TL;DR: Addition of prophylactic levofloxacin to active myeloma treatment during the first 12 weeks of therapy significantly reduced febrile episodes and deaths compared with placebo without increasing health care-associated infections.
Journal ArticleDOI
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
Helena M. Earl,Louise Hiller,Anne-Laure Vallier,Shrushma Loi,Donna L. Howe,Helen B Higgins,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Janine Mansi,Jean Abraham,Carlos Caldas,Claire Hulme,David Miles,Andrew M Wardley,David Cameron,Janet A. Dunn +19 more
TL;DR: PERSEPHONE is a randomised phase 3 non-inferiority trial comparing 6 to 12m trastuzumab, the largest reduced-duration non-InferIORity trial internationally.
Journal ArticleDOI
Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial
Jms Bartlett,Peter Canney,A. M. Campbell,David Cameron,Jenny L Donovan,Janet A. Dunn,Helena M. Earl,Adele Francis,Peter Hall,V. Harmer,Helen B Higgins,L. Hillier,Claire Hulme,Luke Hughes-Davies,Andreas Makris,Adrienne Morgan,Christopher McCabe,Sarah E Pinder,Christopher J. Poole,Daniel Rea,Nigel Stallard,Robert Stein +21 more
TL;DR: The OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.
Journal ArticleDOI
Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients
Mark T. Drayson,Stella Bowcock,Tim Planche,Gulnaz Iqbal,Jill Wood,Kerry Raynes,Guy Pratt,Kwee Yong,Peter M. Hawkey,Helen B Higgins,Janet A. Dunn +10 more
TL;DR: A randomised, double-blind, placebo-controlled multi-centre phase III clinical trial assessing the benefits of antibiotic prophylaxis and its effect on healthcare associated infections showed a significant benefit for the use of levofloxacin.